Summer Camp 2026

The Diabetes Virtual Summer Camp 2026 is a 2-week virtual research internship program that invites high school, college, graduate, and professional students, medical residents, clinical fellows, postdoctoral researchers, early-career clinicians and scientists, physicians (academic or private), researchers (academic or industry), professors, pharmacists, faculty, administrators, entrepreneurs, and other healthcare professionals interested in learning about diabetes research, education, and care as well as biomedical research and academic medicine. The program, partnered with the American Diabetes Association (ADA), consists of 13 Zoom sessions that highlight current topics in diabetes research and treatment as well as career paths in medicine and science. The sessions are led by 9 Experts, who are renowned diabetes researchers and clinicians from reputable universities and institutions across the country. The interactive sessions include a post-session Q&A period following each expert session, a pre-session Q&A period preceding each day’s sessions, an open mic forum at the end of the day’s sessions, and post-session tasks to be completed by the interns. As part of the ADA Scholars Program, the virtual program is intended for students, trainees, clinicians, researchers, faculty, and health professionals sharing a common goal of improving diabetes research, education, and care. The program is free to all registered attendees, who will receive a program certificate upon completion and fulfilling the program requirements. The mission of the Diabetes Virtual Camp is to educate the next generation of physicians and scientists from all around the world, leading the paths to address health inequity while finding a cure for diabetes. We invite you to visit the News page to learn more about the past and upcoming programs and follow us on social media, Facebook, Instagram, and LinkedIn.


Date: August 3, 2026 ~ August 14, 2026

Sessions: Mondays, Wednesdays, and Fridays at 11 am ~ 12:15 pm ET (Eastern Time), except the Closing Sessions on Aug. 14 will end at 1 pm.

This virtual program is free to all registered attendees. Registration is now closed, and we hope to have you in next summer’s program.


Stories from our 2025 Participants

Our recent research, just published in Nature Communications on June 29, 2024, unveils a new and exciting role of IFNgamma-IL12 axis in regulating intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease (MASLD). Despite the fact that metabolic liver disease is an emerging health issue affecting one in four adults in the U.S., 30% of individuals over 60 years old, and 75% of subjects with obesity, there is currently only 1 drug recently approved by the FDA for treating metabolic dysfunction-associated steatohepatitis (MASH). To that end, our findings identify critical roles for the IFNgamma-IL12 axis in modulating obesity-mediated insulin resistance, inflammation, and fatty liver progression to MASH, paving the way for future development of drugs selectively targeting IFNgamma signaling and IL-12 as potential therapies to treat metabolic liver disease in humans. Our research is funded by a recently awarded R01 grant from the National Institutes of Health (1R01-DK133772). This article can be found at https://doi.org/10.1038/s41467-024-49633-y.

Diabetes Virtual Camp is supported in-part by: